Venetoclax and Lintuzumab-Ac225 in AML Patients

Recruiting

Phase 1

Phase 2

Venetoclax and Lintuzumab-Ac225 in AML PatientsVenetoclax and Lintuzumab-Ac225 in AML Patients

Sponsor:

Actinium Pharmaceuticals

Code:

NCT03867682

Conditions

Acute Myeloid Leukemia

Relapsed Adult AML

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Lintuzumab-Ac225

Venetoclax

Spironolactone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Actinium Pharmaceuticals on 2023-08-04.